Riskstratifiering vid pulmonell arteriell hyper­tension - Ger bättre behandling och prognos – högspecialiserat omhändertagande vid universitetssjukhusen krävs

• Pulmonary arterial hypertension (PAH) is a progressive vascular disease, due to vasoconstriction and remodelling of pulmonary arteries. Survival has from diagnosis, if untreated, been found to be 1 to 2.8 years, depending on whether related to rheumatic disease or not. The ESC/ERS risk stratification tool provides a new approach to evaluate the clinical status of PAH patients. It supports a refined treatment strategy, based on risk assessment at diagnosis and early follow-up, with the aim to identify patients early and initiate, as well as adjust treatment individually, striving for the patients to remain in, or improve to low risk status, whereby survival is markedly improved.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)

Publikations- och innehållstyp

art (ämneskategori)

ref (ämneskategori)